Xcout Intel
CrossBridge Bio, Inc.
CrossBridge Bio, Inc. is a medical technology and biopharmaceutical company pioneering an approach to deliver the next generation of stable antibody-drug conjugates (ADCs).
Subscribe to see CrossBridge Bio, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
CrossBridge Bio, Inc. at a glance
CrossBridge Bio, Inc. is a company headquartered in United States. It has raised at least $25M across the 2 funding rounds on record. Its most recent funding round, Grant, raised $15M in November 2025. Xcout tracks 9 named people at CrossBridge Bio, Inc., including Michael Torres (Chief Executive Officer).
CrossBridge Bio, Inc. leadership
- Michael TorresChief Executive Officer
- Zhiqiang AnPromoter
- Zhiqiang F. AnPromoter
- Kyoji TsuchikamaExecutive Officer
- Michael TorresExecutive Officer
- Damir F. IllichDirector
3 more named people on record for CrossBridge Bio, Inc., with roles, board committees and tenure — see the full roster →
CrossBridge Bio, Inc. funding rounds
At least $25M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Grant | $15M | 2 named | |
| Seed | $10.8M | 5 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent CrossBridge Bio, Inc. news
Investors
CrossBridge Bio, Inc. competitors
A few of CrossBridge Bio, Inc.'s closest competitors — see the full list of competitors and alternatives →
Crossbow Therapeutics is a privately held biotechnology company founded in 2021 and headquartered in Cambridge, Massachusetts. The company develops potent antibody therapeutics aimed at expanding treatment options and combating cancer.
Centrose LLC is a biotechnology company that develops a next-generation antibody-drug conjugate platform known as Extracellular Drug Conjugates (EDCs). These precision medicines target the cell surfaceome by binding multiple extracellular proteins simultaneously without cell internalization or drug release, aiming to create safer and more potent treatments for cancer and drug-resistant tumors.
Adcytherix is a clinical-stage biopharmaceutical company that develops next-generation antibody-drug conjugates (ADCs) for oncology. The company combines clinically validated targets with innovative payloads derived from approved cancer drugs to treat resistant cancers and address unmet medical needs.
VelosBio Inc. is a clinical-stage biopharmaceutical company based in California, United States, focused on developing novel antibody-drug conjugates to transform cancer treatment for patients.
BrickBio, Inc. is a Boston-based biotechnology company focused on protein bioconjugation. The company empowers next-generation therapeutics using proprietary platforms such as BrickADCs and Protein Origami.
Lifordi Immunotherapeutics, Inc. is a clinical-stage biotechnology company based in Burlington, Massachusetts, focused on developing antibody-drug conjugates (ADCs).
Get CrossBridge Bio, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on CrossBridge Bio, Inc. in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access